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Recently, we reported that hemebinds to tumor suppressor p53 pro-
tein (TP53, best known as p53) and pro-
motes its nuclear export and cytosolic
degradation, whereas iron chelation sta-
bilizes p53 protein and suppresses
tumors in a p53-dependent manner. This
not only provides mechanistic insights
into tumorigenesis associated with iron
excess, but also helps guide the adminis-
tration of chemotherapy based on iron
deprivation in the clinic.
Numerous studies have established that
iron excess caused by dietary, environmen-
tal, or genetic factors can significantly
promote tumorigenesis.1,2 Hereditary
hemochromatosis (HH), a genetic disor-
der that leads to iron overload, affects
nearly 1 in 300–400 of the white popula-
tion in the United States alone. Clinical
complications in HH patients typically
include liver cirrhosis and up to a 20- to
200-fold increased risk of hepatocellular
carcinoma or other cancer types, although
the underlying mechanisms remain elu-
sive.3 Moreover, tumors reprogram iron
metabolism to achieve advantages in
growth, proliferation, and/or metastasis.2
Iron deprivation, through iron chelation
or application of transferrin receptor
(TFR)-neutralizing antibodies, has
emerged as a major strategy for chemo-
therapy. However, iron deprivation only
suppresses select types of human malig-
nancies while exerting no effects on other
types of cancer.4 We recently reported a
link between iron metabolism and tumor
suppressor p53 function, providing mech-
anistic insight into both the increased
tumorigenesis associated with iron over-
load and the selective therapeutic efficacy
of iron deprivation-based chemotherapy.
Tumor suppressor p53 (TP53, hereaf-
ter referred to as p53) suppresses tumori-
genesis and regulates DNA damage repair,
cell-cycle arrest, and tumor responses to
chemotherapy, while also serving as a hub
in the control of cellular metabolism.5 A
few small molecules, such as NADC and
ADP, have been identified as potential
physiological ligands for p53 protein that
can modulate changes in p53 signaling in
response to perturbation in cell redox state
and energy metabolism. It remains unclear
whether and how other metabolites or sig-
naling molecules might bind to p53 and
modulate its function in vivo.
Heme, an iron polyporphyrin, is a
major form of intracellular bio-iron that
constitutes the prosthetic group for pro-
teins that function in myriad fundamental
biological processes, including respiration,
energetic homeostasis, signal transduction,
xenobiotic detoxification, iron metabo-
lism, mRNA processing, control of circa-
dian rhythm, and some protein
degradation pathways.6-9 As more heme–
protein interactions continue to be identi-
fied, it is reasonable to believe that we
may be only just beginning to understand
the influence of heme on biological
functions.
In our recent report, we showed that
levels of both intracellular iron and heme
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are elevated 6- to 9-fold in the livers of
Hfe¡/¡ mice compared to wild-type mice.
The HFE gene, standing for high Fe, enc-
odes a protein that functions in iron
absorption by regulating the interaction of
the transferrin receptor with transferrin;
Hfe¡/¡ mice are a mouse model for
human HH, in which the static level of
tumor suppressor p53 protein is signifi-
cantly downregulated.10 Cell-based expe-
riments further indicate that heme acceler-
ates proteasome-dependent degradation of
p53 protein, whereas deferoxamine
(DFO), an iron chelator, has the opposite
effect. We next demonstrated that heme
directly binds to p53 protein, apparently
through the heme regulatory motif in the
DNA-binding domain of p53. Such bind-
ing interferes with the interactions
between p53 and its target DNA. Heme
binding may also induce conformational
changes in p53 and expose its C-terminal
nuclear exporting sequences, thus promot-
ing interaction of p53 with chromosomal
region maintenance 1 (CRM1)/exportin-
1 and facilitating the nuclear export of
p53 and its subsequent cytosolic degrada-
tion. As a result, cellular p53 signaling is
downregulated during iron or heme
excess.
Similarly, we found that heme also
binds and destabilizes p63 and p73, the
other 2 members of the p53 protein fam-
ily. Thus, the p53 protein family members
contain the heme regulatory motif, bind
to heme, and undergo accelerated degra-
dation upon hemin treatment. It is con-
ceivable that heme-induced nuclear export
and destabilization of p53 family proteins,
along with the ensuing functional changes,
also exerts effects at the organismal level.
Iron overload and accumulation of heme
in afflicted cells or tissues eventually leads
to increased production of reactive oxygen
species (ROS) and damage to intracellular
structures including proteins and DNA,2
a situation in which normally functioning
p53, the “guardian of the genome,” would
be essential to mitigate these insults and
promote cell survival. However, heme-
induced nuclear export and destabilization
of p53 and other proteins may exacerbate
the insults, thus contributing to the patho-
genesis of disorders associated with iron
excess, such as the tendency for tumori-
genesis observed in hemochromatosis. It is
intriguing to ask whether heme-acceler-
ated degradation of p53 might play a
role in other pathogenic features of
hemochromatosis.
Through experiments using isogenic
HCT116 human colon cancer cells and
their p53-null mutants in cell culture and
a tumorigenicity model, we were able to
show that the tumor-suppressing effect of
DFO relies on wild-type p53 signaling.
Furthermore, iron deprivation induced by
DFO was found to suppress multiple
types of human tumor cell lines with pre-
dominantly wild-type p53 signaling but
not p53-null cell lines, suggesting that
upregulation of wild-type p53 signaling
might critically underlie the selective effi-
cacy of iron deprivation. Therefore, this
work not only offers mechanistic insights
Figure 1. Schematic showing how iron metabolism might regulate p53 signaling and tumorigenesis. Heme directly binds to p53 protein and downregu-
lates p53 signaling by interfering with p53–DNA interaction and promoting nuclear export of p53 and its subsequent cytosolic proteolysis. p53 refers to
tumor suppressor p53 (TP53); CRM1, chromosomal region maintenance 1/exportin 1; Ub, ubiquitin.
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into tumorigenesis associated with iron or
heme excess (see Fig. 1 for a schematic
view of the proposed mechanism), but
also provides a molecular basis for chemo-
therapy based on iron deprivation.
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